(BLTE) Belite Bio - Ratings and Ratios
Oral Therapy, Stargardt, Geographic Atrophy, Liver Disease
| Risk via 10d forecast | |
|---|---|
| Volatility | 89.2% |
| Value at Risk 5%th | 108% |
| Relative Tail Risk | -26.51% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.72 |
| Alpha | 25.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.345 |
| Beta | 0.335 |
| Beta Downside | 0.470 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.63% |
| Mean DD | 15.36% |
| Median DD | 11.94% |
Description: BLTE Belite Bio November 10, 2025
Belite Bio, Inc. (NASDAQ: BLTE) is a clinical-stage biopharma focused on oral therapeutics for retinal degenerative diseases that lack approved treatments in the United States. The company was founded in 2016, is headquartered in San Diego, and operates as a subsidiary of Lin Bioscience International Ltd.
Its lead candidate, Tinlarebant (LBS-008), is an orally administered drug currently in a Phase 3 trial as an early-intervention therapy for Stargardt disease type 1 and geographic atrophy (GA). Both conditions are forms of age-related macular degeneration, a market estimated at ≈ $6 billion globally in 2023, with GA alone representing roughly 10 % of that spend (source: GlobalData). Successful Phase 3 data could position Tinlarebant as the first oral disease-modifying option in a space dominated by intravitreal injections.
Belite’s secondary pipeline includes LBS-009, an anti-retinol-binding protein 4 (RBP4) oral agent in preclinical development. LBS-009 is being positioned for metabolic indications such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and gout-areas collectively representing a $70 billion addressable market in the U.S. alone (based on 2022 IQVIA estimates). Progress to IND filing would be a material catalyst for the company.
From a financial standpoint, Belite reported cash and cash equivalents of roughly $45 million as of its latest 10-Q (Q2 2024), giving it an estimated 12-month runway at current burn rates (~$3–4 million per month). The biotech sector’s fundraising environment remains relatively tight, with average Q-cycle financing down 15 % YoY, implying that additional capital may need to be raised if trial timelines extend. Moreover, the company’s valuation (~$150 million market cap) reflects a price-to-cash multiple of ~3.3×, which is modest compared with peer averages of 5–7× for Phase 3-ready retinal programs.
For a deeper quantitative assessment-including scenario-based valuation and sensitivity to Phase 3 outcomes-exploring the analytics on ValueRay can help you gauge the risk-adjusted upside of BLTE’s pipeline.
BLTE Stock Overview
| Market Cap in USD | 4,079m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-04-29 |
| Return 12m vs S&P 500 | 18.3% |
| Analyst Rating | 4.60 of 5 |
BLTE Dividends
Currently no dividends paidBLTE Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 50.49% |
| CAGR/Max DD Calmar Ratio | 0.76 |
| CAGR/Mean DD Pain Ratio | 3.29 |
| Current Volume | 146.5k |
| Average Volume | 83.7k |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.10 (>2.0%) and ΔFCFTA 15.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.10 (>3.0%) and CFO -29.2m > Net Income -62.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 45.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (33.2m) change vs 12m ago 8.26% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2165 (EBITDA TTM -61.0m / Interest Expense TTM 20.0k) >= 6 (WARN >= 3) |
Altman Z'' -10.09
| (A) 0.96 = (Total Current Assets 277.2m - Total Current Liabilities 6.05m) / Total Assets 282.4m |
| (B) -0.38 = Retained Earnings (Balance) -107.6m / Total Assets 282.4m |
| (C) -0.22 = EBIT TTM -43.3m / Avg Total Assets 199.1m |
| (D) -13.03 = Book Value of Equity -108.3m / Total Liabilities 8.31m |
| Total Rating: -10.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.91
| 1. Piotroski 0.0pt |
| 2. FCF Yield -0.75% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 0.51 |
| 6. ROIC - WACC (= -36.94)% |
| 7. RoE -34.29% |
| 8. Revenue Trend data missing |
| 9. EPS Trend -30.35% |
What is the price of BLTE shares?
Over the past week, the price has changed by -2.87%, over one month by +20.81%, over three months by +72.15% and over the past year by +32.29%.
Is BLTE a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BLTE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 113.8 | 4.2% |
| Analysts Target Price | 113.8 | 4.2% |
| ValueRay Target Price | 141.1 | 29.3% |
BLTE Fundamental Data Overview November 19, 2025
P/B = 14.9197
Beta = -1.423
Revenue TTM = 0.0 USD
EBIT TTM = -43.3m USD
EBITDA TTM = -61.0m USD
Long Term Debt = 537.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 276.0k USD (from shortTermDebt, last fiscal year)
Debt = 537.0k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -31.1m USD (from netDebt column, last fiscal year)
Enterprise Value = 3.93b USD (4.08b + Debt 537.0k - CCE 145.1m)
Interest Coverage Ratio = -2165 (Ebit TTM -43.3m / Interest Expense TTM 20.0k)
FCF Yield = -0.75% (FCF TTM -29.4m / Enterprise Value 3.93b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 67.6m) / Revenue TTM)
Tobins Q-Ratio = 13.93 (Enterprise Value 3.93b / Total Assets 282.4m)
Interest Expense / Debt = 3.72% (Interest Expense 20.0k / Debt 537.0k)
Taxrate = -0.0% (0.0 / -21.7m)
NOPAT = -43.3m (EBIT -43.3m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 45.82 (Total Current Assets 277.2m / Total Current Liabilities 6.05m)
Debt / Equity = 0.00 (Debt 537.0k / totalStockholderEquity, last quarter 274.1m)
Debt / EBITDA = 0.51 (negative EBITDA) (Net Debt -31.1m / EBITDA -61.0m)
Debt / FCF = 1.06 (negative FCF - burning cash) (Net Debt -31.1m / FCF TTM -29.4m)
Total Stockholder Equity = 182.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.09% (Net Income -62.4m / Total Assets 282.4m)
RoE = -34.29% (Net Income TTM -62.4m / Total Stockholder Equity 182.0m)
RoCE = -23.72% (EBIT -43.3m / Capital Employed (Equity 182.0m + L.T.Debt 537.0k))
RoIC = -29.69% (negative operating profit) (NOPAT -43.3m / Invested Capital 145.8m)
WACC = 7.25% (E(4.08b)/V(4.08b) * Re(7.25%) + D(537.0k)/V(4.08b) * Rd(3.72%) * (1-Tc(-0.0)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 8.32%
Fair Price DCF = unknown (Cash Flow -29.4m)
EPS Correlation: -30.35 | EPS CAGR: -56.76% | SUE: -2.49 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for BLTE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle